Open AccessAnalyzing epidermal growth factor receptor mutation status changes in advanced non‐small‐cell lung cancer at different sampling time‐points of blood within one day
Author(s) -
Wang Jin,
Bai Hua,
Hong Chaoyu,
Wang Jie,
Mei Tonghua
Publication year - 2017
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12443
Subject(s) - gefitinib , medicine , lung cancer , epidermal growth factor receptor , oncology , digital polymerase chain reaction , tyrosine kinase inhibitor , blood sampling , lung , tyrosine kinase , circulating tumor dna , mutation , kinase , epidermal growth factor , cancer research , cancer , receptor , polymerase chain reaction , gene , biology , biochemistry , microbiology and biotechnology
Background We investigated whether different sampling time‐points within one day would influence epidermal growth factor receptor mutation ( EGFRm ) status in plasma and evaluated the clinical outcomes according to the quantity analysis of EGFRm in circulating tumor DNA ( ctDNA ) in non‐small‐cell lung cancer ( NSCLC ). Methods EGFR‐tyrosine kinase inhibitor naïve advanced NSCLC patients who carried EGFR m in both tissues and ct DNA were enrolled in this study. Plasma samples were collected at three time‐points within one day (at 8 am, 11 am and 2 pm) for EGFR m analysis by droplet digital PCR . Results Twenty‐two advanced NSCLC patients were enrolled in the study. In a total of 66 blood specimens, the median EGFR m frequency was 7.13% (range 0–35.09%), and among them six specimens had less than 1.0% EGFRm frequency. Moreover, one time‐point blood specimen did not display any EGFR m, even by droplet digital PCR . The frequency of EGFR m changed dynamically across different time‐points within one day, but the differences were not significant ( P = 0.557). We observed that patients with a relatively high frequency of EGFR m (>6.76%) had a better response to gefitinib ( P = 0.024). Conclusion The release of ctDNA maybe a temporal heterogenous process. The different sampling time‐points within one day did not seem to influence EGFR m status in ctDNA . The relative EGFR m frequency in ctDNA could predict a benefit of EGFR ‐ tyrosine kinase inhibitor treatment for advanced NSCLC patients .